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Background: We explored the relationship between epicardial adipose tissue (EAT) volume, body mass index
(BMI) and the incidence of major coronary events in non-obese patients with suspected coronary artery disease
(CAD).
Methods:Wemeasured EAT volume in a cohort of 722 patients who had undergone coronary computed tomog-
raphy, and recorded subsequent occurrences of major coronary events (cardiac death and acute coronary syn-
drome), simultaneously evaluating all coronary events and all-cause death.
Results: Eighteen patients experienced major coronary events: there were ﬁve cardiac deaths and 13 cases of
acute coronary syndrome. BMI was inversely predictive of major coronary events (hazard ratio [HR], 0.74; 95%
conﬁdence interval [CI], 0.63–0.87; p b 0.001), but not for all-cause death. EAT volume predicted all coronary
events (HR per 10 mL, 1.11; 95% CI, 1.03–1.19; p= 0.003). Although there was a trend suggestive of an inverse
association with major coronary events, this was not statistically signiﬁcant (HR per 10 mL, 1.10; 95% CI;
1.00–1.21; p = 0.059), and there was no signiﬁcant relationship with all-cause death. When stratiﬁed by the
ﬁrst quartile (QI) of BMI (≤21.4 kg/m2) andmedian EAT volume (107mL), the event rates in the high EAT volume
and BMI QI group were signiﬁcantly higher than those of other groups (adjusted HR, 5.45; 95% CI, 1.51–25.3 p=
0.009, compared with the low EAT volume and BMI QI group).
Conclusion: Our ﬁndings suggest that suspected CAD patients with low BMI but high EAT volume are at an in-
creased risk of major coronary events, but not all-cause death.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Elevated epicardial adipose tissue (EAT) volume is reportedly associ-
atedwith coronary artery disease (CAD) [1,2], acute coronary syndrome
[3] and the presence of non-calciﬁed plaques detected by coronary
computed tomography (CT) angiography [4,5]. In a prospective
population-based cohort study, the presence of epicardial fat was
found to be associated with fatal and non-fatal coronary events in the
general population, independently of traditional cardiovascular risk fac-
tors [6]. Meanwhile, there have been several reports that elevated EAT
volumemay be an important factor in the development of cardiovascular
disease, especially in non-obese individuals [7–9].We previously demon-
strated that high EAT volume is independently and incrementally predic-
tive of future coronary events – including coronary revascularization – inascular Medicine, Hiroshima
iences, 1-2-3 Kasumi Minami-
x: +81 82 257 1569.
mamoto).
nd Ltd. This is an open access article upatients without proven CAD [10]. Our ﬁndings also suggested that pa-
tients with low body mass index (BMI) but high EAT volume may be at
higher risk of coronary events [10].
We sought to evaluate the relationships between EAT volume, BMI
and mortality and coronary morbidity in a long-term follow-up study
of a cohort of patients with suspected CAD who had undergone coro-
nary CT. We focused the purpose of the present study especially to the
occurrences of major coronary events (deﬁned as cardiac death or a di-
agnosis of acute coronary syndrome), and simultaneously evaluated all-
cause death and coronary events including coronary revascularizations.
2. Methods
2.1. Study population
This study was performed as a sub-analysis of a previous study; pa-
tient selection and investigation have been described previously [10].
Brieﬂy, 1081 patients underwent non-contrast enhanced cardiac CT in
our institution for the purposes of diagnosis and coronary artery calciumnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cohort of thosewith suspectedCADwas selectedby excluding thosewith:
proven CAD with a history of myocardial infarction (MI); prior coronary
revascularization; acute coronary syndrome or typical effort angina;
proven cardiomyopathy; severe valvular heart disease; renal impairment
(serum creatinine concentration ≥1.5 mg/dL); or serious life-threatening
illness. We also excluded those who underwent coronary revasculariza-
tion within 3 months of CT (n= 76) and those followed up for b1 year
(n=52). Finally, 722 patients were included in the analysis. The conduct
of the study was approved by the ethics committee of Hiroshima
University.
2.2. Risk factor assessments
Patients' demographic characteristics, medical history andmedication
use were recorded at the clinical consultation. As previously described,
traditional coronary risk factors were determined, and blood samples
were taken for routine laboratory testing, including the serum concentra-
tions of high-density lipoprotein (HDL)- and low-density lipoprotein
(LDL) cholesterol, triglycerides and C-reactive protein (CRP) [10,11].
2.2.1. Coronary CT imaging protocol and CAC scoring
Images were acquired between November 2004 and September 2009
using either a 16- or 64-slice CT scanner (LightSpeed Ultrafast16 or
LightSpeed VCT, GE Healthcare, Waukesha, WI). Prospective ECG-
triggered scans were performed in mid-inspiration from the root of the
aorta to the cardiac apex using the following parameters for 16-slice CT
and 64-slice CT, respectively: axial scan gantry rotation times, 500 ms
and 350 ms; X-ray exposure times, 333 ms and 233 ms; tube voltage,
120 kV for both; tube currents, 100mAand140mAand center of imaging
window, 75% of R–R interval for both. Forty-eight contiguous images of
2.5-mm thickness were obtained, and the total CAC score was calculated
based on the Agatston method using dedicated software (Smartscore,
version 3.5, GE Healthcare) [10,12].
2.2.2. Measurement of EAT
EAT was deﬁned as that seen surrounding the myocardium but lim-
ited by the epicardium on plain CT images acquired for CAC scoring. EAT
quantiﬁcationswere performed using dedicated software formeasuring
visceral adipose tissue area (Virtual Place, Aze Inc., Tokyo, Japan). With-
in the region of interest, fat was deﬁned as pixels with a density be-
tween −250 and −30 Hounsﬁeld units. EAT area was manually
traced around the epicardium and automatically quantiﬁed. EAT vol-
ume was measured by calculating the sum of the EAT areas measured
from 1 cm above the left main coronary artery to the left ventricularTable 1
Patients' baseline clinical characteristics by body mass index quartile.
BMI quartile range (kg/m2) QI; ≤21.4 (N = 175) QII; 21.5–23.3 (N = 1
Age (years) 66.6 ± 11.5 64.5 ± 11.4
Male 79 (45) 65 (35)
Hypertension 84 (48) 98 (53)
Diabetes mellitus 61 (34) 43 (23)
Hypercholesterolemia 72(41) 75 (41)
Current smoking 51 (29) 62 (34)
Current cardiac symptoms 53 (30) 66 (36)
Serum LDL cholesterol (mg/dL) 114 ± 32 120 ± 33
Serum HDL cholesterol (mg/dL) 64 ± 16 62 ± 17
Serum creatinine (mg/dL) 0.75 (0.64–0.88) 0.80 (0.69–0.93)
Serum CRP (mg/L) 0.4 (0.2–0.9) 0.5 (0.3–1.0)
EAT volume (mL) 87.1 ± 36.2 103.5 ± 38.1
CAC score 32 (0–181) 10 (0–97)
Medications
Anti-hypertensive agents 61 (35) 69 (38)
Statins 46 (27) 39 (21)
Hypoglycemic agents 51 (29) 29 (16)
Values are expressed as number (percent), mean ± SD, or median (interquartile range).
Abbreviations: BMI, bodymass index; CAC, coronary artery calcium;CRP, C-reactive protein; EATapex at 1-cm intervals. The operators were blinded to any clinical char-
acteristics and outcomes [5,10].
2.2.3. Long-term prognosis
Follow-up data were obtained frommedical records, by telephone in-
terviews of patients or their families, or by questionnaires for patients or
their primary care physicians. Outcome measures were all-cause death
and occurrences of coronary events. Coronary events were deﬁned as
major if there was cardiac death, non-fatal MI or unstable angina requir-
ing urgent hospitalization. All coronary events included major coronary
events and elective coronary revascularizations ≥3 months after CT. All
endpoints were determined by consensus between two board-certiﬁed
cardiologists blinded to the results of CT angiography, and who were
not aware of the clinical history or details of previous hospitalizations
[10].
2.3. Statistics
The serum creatinine, CRP and triglyceride concentrations and CAC
score are expressed as medians (interquartile range). Other measure-
ments are expressed as mean± standard deviation. Categorical variables
are reported as the number (proportion, %) and were compared using
Pearson's chi-square test. Analysis of variance or the Kruskal–Wallis test
was used for group comparisons of continuous variables. Tukey's test
was used for analysis of variables that were normally distributed, and
the Steel–Dwass method for those that were not. Patients were divided
into quartiles on the basis of BMI and EAT volume (QI represents the
ﬁrst quartile, QII the second, QIII the third, and QIV the fourth quartile).
Event rates were estimated by Kaplan–Meier curves and compared
using log-rank tests. Coxproportional hazardsmodelswere used todeter-
mine predictors of events. Hazard ratios (HR) with 95% conﬁdence inter-
vals (CI) were calculated using a univariatemodel, a multivariate age and
sex-adjusted model, and a multivariate model adjusted for age, sex, and
confounders that yielded ap-value b 0.05 in theunivariate analysis. Statis-
tical analyses were performed using SPSS 21.0 (IBM Inc., Chicago, IL).
A p-value b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Baseline characteristics
Patients' baseline clinical characteristics and CT ﬁndings were com-
pared by BMI quartile (Table 1). Age and serum HDL cholesterol concen-
tration were inversely correlated with increasing BMI quartiles. The
serum concentrations of LDL cholesterol, creatinine and CRP, and EAT83) QIII; 23.4–25.6 (N = 181) QIV; ≥25.7 (N = 183) p-Value
65.8 ± 9.8 63.3 ± 10.6 0.024
64 (35) 73 (40) 0.18
113 (62) 124 (67) b0.001
65 (36) 67 (37) 0.025
92 (51) 88 (48) 0.14
57 (31) 52 (28) 0.64
71 (39) 74 (41) 0.18
123 ± 29 124 ± 32 0.014
60 ± 17 55 ± 18 b0.001
0.81 (0.68–0.91) 0.78 (0.66–0.90) 0.034
0.5 (0.3–1.3) 0.9 (0.4–1.8) b0.001
118.0 ± 39.4 137.7 ± 42.1 b0.001
38 (0–175) 16 (0–163) 0.093
93 (51) 92 (50) 0.0012
53 (29) 48 (26) 0.37
42 (23) 40 (22) 0.027
, epicardial adipose tissue;HDL, high-density lipoprotein and LDL, low-density lipoprotein.
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was no signiﬁcant difference in CAC scores between the BMI quartiles.3.2. Long-term event rates and univariate predictors
During the mean 3.7 ± 1.7 year follow-up period, there were 31
deaths (4.3% mortality: ﬁve cardiac deaths, three vascular-related
deaths and 23 non-cardiovascular deaths). Eighteen patients (2.5%) ex-
perienced coronary events: in addition to the ﬁve cardiac deaths, 13 pa-
tients were diagnosed with an acute coronary syndrome.
Table 2 shows univariate analyses to identify predictors of all-cause
death andmajor- and all coronary events. Age (HR per 10 year increase,
1.94; 95% CI, 1.16–3.32; p=0.009) and log-transformed CAC score (HR
per doubling of the CAC score, 1.16; 95% CI, 1.02–1.34; p=0.020) were
signiﬁcantly predictive of major coronary events. There was a non-
signiﬁcant trend that suggested a positive relationship between EAT
volume and major coronary events (HR per 10 mL increase, 1.10; 95%
CI, 1.00–1.21; p=0.059). There was a signiﬁcantly inverse relationship
between BMI and major coronary events (HR, 0.74; 95% CI; 0.63–0.87;
p b 0.001), but not for all-causemortality or all coronary events. EAT vol-
ume was signiﬁcantly predictive of all coronary events (HR per 10 mL
increase, 1.11; 95% CI; 1.03–1.19; p = 0.003), whereas there was a
non-signiﬁcant trend suggestive of an inverse relationship with major
coronary events (HR per 10 mL increase, 1.10; 95% CI; 1.00–1.21; p =
0.059) and no signiﬁcant relationship with all-cause deaths.3.3. Long-term event rates stratiﬁed by BMI and EAT volume
The incidences of all-cause deaths and major- and all-coronary
events were compared between each of the BMI and EAT volume quar-
tiles. The annual incidence ofmajor coronary eventswas inversely relat-
ed with BMI quartile (1.5%, 1.0%, 0% and 0.1% for QI to IV, respectively;
p b 0.001). Therewere no signiﬁcant relationships between BMI quartile
and either the incidence of all-coronary events or all-cause death. In
contrast, there was a statistically signiﬁcant positive relationship be-
tween EAT volume quartile and the incidence of all coronary events
(1.0%, 0.4%, 2.0% and 2.1% for QI to QIV, respectively; p= 0.014); how-
ever, there were no signiﬁcant differences in the incidences of all-cause
death or major coronary events (Fig. 1).Table 2
Univariate analysis to identify predictors of all-cause death and major- and all coronary events
Variable All-cause death
univariate HR
(95% CI)
p-Value
Age (per 10 year increase) 1.10 (1.26–1.62) b0.001
Male 2.29 (1.04–5.77) 0.039
BMI (per 1 kg/m2 increase) 0.93 (0.83–1.03) 0.15
BMI QI 1.68 (0.78–3/44) 0.18
Hypertension 0.89 (0.44–1.82) 0.73
Diabetes mellitus 0.51 (0.21–1.94) 0.085
Hypercholesterolemia 0.66 (0.31–1.35) 0.26
Current smoking 1.20 (0.55–2.46) 0.63
Current cardiac symptoms 1.80 (0.87–3.67) 0.12
Serum LDL cholesterol (10 mg/dL increase) 0.97 (0.86–1.86) 0.60
Serum HDL cholesterol (10 mg/dL increase) 0.95 (0.77–1.11) 0.61
Serum CRP (1 mg/L increase) 1.16 (1.08–1.23) 0.001
Serum creatinine (1 mg/dL increase) 1.08 (0.43–1.54) 0.80
EAT volume (10 mL increase) 0.99 (0.91–1.07) 0.64
Log2 (CAC score + 1) 1.25 (1.12–1.41) b0.001
Anti-hypertensive agent 1.33 (0.65–2.71) 0.44
Hypoglycemic agent 0.52 (0.19–1.22) 0.14
Abbreviations: BMI, bodymass index; BMI QI, bodymass index lowest quartile; CAC, coronary a
sue; HDL, high-density lipoprotein; HR, hazard ratio and LDL, low-density lipoprotein,.3.4. Major coronary event rates stratiﬁed by BMI and EAT volume
Weexamined the incidence ofmajor coronary events by re-stratifying
the cohort, subdividing BMI into two groups (QI, BMI ≤ 21.4 kg/m2 and
QII–IV, BMI ≥ 21.5 kg/m2) and EAT volume into two groups based on
the median (low EAT volume b107 mL and high EAT volume ≥107 mL).
In Table 3, univariate and multivariate analyses demonstrated that
major- and all coronary events were signiﬁcantly higher in the BMI QI,
high EAT volume group compared with reference (BMI QI, low EAT vol-
ume) group, but there were no signiﬁcant differences in the all-cause
mortality. The Kaplan–Meier curves show that the major coronary event
rate in the BMI QI, high EAT volume group was signiﬁcantly greater
than the three other groups. We found that after adjusting for age, sex
and log-transformed CAC score, the BMI QI and high EAT volume group
was at more than a ﬁvefold increased risk of a major coronary event
than the BMI QI low EAT volume group (HR, 5.45; 95% CI, 1.51–25.3;
p= 0.009; Fig. 2).
4. Discussion
In our previous study which sought to examine the incremental pre-
dictive value of EAT volume on CAC score to all coronary events including
cardiac death, acute coronary syndrome, and coronary revascularization,
we found that patientswith low BMI but high EAT volumewere at higher
risk of all coronary events [10]. In thepresent study,we sought to evaluate
the relationships between BMI, EAT volume and long-termoutcomes.We
focused the purposes to evaluate major coronary events and all-cause
death. We found an elevated risk of major coronary events in those
with a lower BMI but high EAT volume, but no relationship between
EAT volume and all-causemortality. These ﬁndings support the hypothe-
sis that development of coronary atherosclerosis may be associated with
accumulation of EAT, provoked by inﬂammatory cytokines released from
EAT in addition to systemic inﬂammation andmetabolic disorders [8,13].
4.1. The obesity paradox and cardiovascular mortality and morbidity
We found that the incidence of major coronary events was inversely
related to BMI quartile in patients with suspected CAD, but therewas no
relationship with all-cause mortality or the incidence of all coronary
events. Previous meta-analyses have revealed a U-shaped relationship.
Major-coronary
event univariate HR
(95% CI)
p-Value All-coronary event
univariate HR
(95% CI)
p-Value
1.94 (1.16–3.32) 0.009 1.03 (1.00–1.94) 0.055
1.73 (0.65–5.38) 0.28 1.38 (0.35–1.41) 0.35
0.74 (0.63–0.87) b0.001 0.88 (0.79–0.97) 0.12
3.92 (1.55–10.3) 0.004 1.70 (0.84–3.39) 0.13
1.95 (0.73–6.08) 0.19 2.74 (1.31–6.42) 0.006
2.11 (0.82–5.59) 0.11 1.48 (0.75–2.87) 0.25
1.95 (0.75–5.15) 0.18 1.59 (0.83–3.10) 0.16
1.80 (0.69–4.56) 0.22 1.92 (1.55–3.66) 0.053
1.65 (0.63–4.22) 0.30 1.41 (0.71–2.72) 0.31
0.98 (0.90–1.13) 0.81 1.00 (0.90–1.10) 0.99
1.10 (0.86–1.35) 0.41 1.00 (0.92–1.26) 0.20
1.06 (0.71–1.17) 0.88 1.04 (0.85–1.15) 0.58
1.27 (0.57–1.74) 0.41 1.15 (0.53–1.56) 0.63
1.10 (1.00–1.21) 0.059 1.11 (1.03–1.19) 0.003
1.16 (1.02–1.34) 0.020 1.28 (1.15–1.43) b0.001
1.61 (0.63–4.22) 0.31 1.88(0.98–3.70) 0.056
1.30 (0.44–3.42) 0.62 0.94 (0.43–1.92) 0.87
rtery calcium; CI, conﬁdence interval; CRP, C-reactive protein; EAT, epicardial adipose tis-
Fig. 1. All-cause mortality and major- and all-coronarymorbidities by bodymass index (BMI) quartile (upper) and epicardial adipose tissue (EAT) volume quartile (lower). BMI quartiles
were: QI, ≤21.4 kg/m2; QII, 21.5–23.3 kg/m2; QIII, 23.4–25.6 kg/m2; and QIV, ≥25.7 kg/m2. EAT volume quartiles were: QI, b80 mL; QII, 80 ≤ 107 mL; QIII, 107–135 mL; and QIV, N135 mL.
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Asians: the lowest mortality rate from cardiovascular disease was seen
within the BMI range 20.0–22.4 kg/m2, but mortality was elevated at
BMI ≥ 25 kg/m2 and ≤19.9 kg/m2 [14]. Similarly, O'Brien and colleagues
described a U-shaped relationship between weight and all-cause mor-
tality in a large cohort of patients whohad sustained a non-ST-elevation
MI [15]. It is well recognized that being either overweight or under-
weight increases all-cause mortality [16,17], and that weight loss is
also associated with cardiovascular morbidity [18,19].
In a previous cohort study conducted in Japan, high BMI was associ-
ated with an increased risk of coronary heart disease [20,21]. Men and
women with BMI ≥ 27.0 kg/m2 had a higher mortality from MITable 3
Univariate and multivariate models predicting all-cause death and major- and all coronary eve
Univariate A
HR (95% CI) p-Value H
All-cause death
BMI QI, low EAT volume 1 (ref.) – 1
BMI QI, high EAT volume 3.09 (0.93–10.7) 0.065 2
BMI QII–IV, low EAT volume 1.30 (0.48–4.10) 0.61 1
BMI QII–IV, high EAT volume 0.67 (0.22–2.23) 0.49 0
Major coronary event
BMI QI, low EAT volume 1 (ref.) – 1
BMI QI, high EAT volume 6.54 (1.81–30.4) 0.004 5
BMI QII–IV, low EAT volume 0.54 (0.10–2.92) 0.45 0
BMI QII–IV, high EAT volume 0.69 (0.17–3.38) 0.69 0
All coronary events
BMI QI, low EAT volume 1 (ref.) – 1
BMI QI, high EAT volume 4.46 (1.49–14.8) 0.008 4
BMI QII–IV, low EAT volume 0.53 (0.15–1.91) 0.32 0
BMI QII–IV, high EAT volume 1.60 (0.64–4.81) 0.33 1
BMI QI was ≤21.4 kg/m2 and QII–IV, ≥21.5 kg/m2. Low EAT volume was b107 mL (median) an
⁎Adjusted for age, sex, and log2 (CAC score + 1).
Abbreviations: BMI, body mass index; CAC, coronary artery calcium; CI, conﬁdence interval ancompared with subjects with BMI 23.0–24.9 kg/m2, but mortality was
not increased in those with BMI 19–21.9 kg/m2 [21]. Our ﬁndings do
not allow us to draw any ﬁrm conclusions about the association be-
tween all-cause death and all coronary events, but we did detect a sig-
niﬁcantly higher incidence of major coronary events in those with low
BMI (the lowest quartile in our cohort had BMI ≤ 21.4 kg/m2). The
mean BMI in our study population was 23.5 kg/m2 (75% were less
than 25 kg/m2 and only 3% had BMI greater than 30 kg/m2), broadly
comparable with that of participants in a recent multicenter study of
acute coronary syndrome in Japan (24.5 kg/m2) [22].
Because of the controversial nature of the apparent relationship
among BMI, other risk factors and the incidence and outcomes ofnts stratiﬁed by body mass index and epicardial adipose tissue volume.
ge and sex-adjusted Multivariate⁎
R (95% CI) p-Value HR (95% CI) p-Value
(ref.) – 1 (ref.) –
.66 (0.80–9.27) 0.11 2.53 (0.76–8.82) 0.13
.80 (0.66–5.69) 0.26 1.86 (0.68–5.88) 0.23
.69 (0.23–2.31) 0.53 0.70 (0.23–2.25) 0.51
(ref.) – 1 (ref.) –
.77 (1.59–26.8) 0.007 5.45 (1.51–25.3) 0.009
.55 (0.10–3.03) 0.48 0.67 (0.12–3.66) 0.63
.63 (0.15–3.08) 0.53 0.66 (0.16–3.25) 0.58
(ref.) – 1 (ref.) –
.08 (1.35–13.6) 0.012 3.91 (1.30–13.0) 0.015
.57 (0.16–2.034) 0.37 0.67 (0.19–2.42) 0.53
.53 (0.61–4.62) 0.38 1.49 (0.60–4.51) 0.41
d high EAT volume, ≥107 mL.
d EAT, epicardial adipose tissue.
Fig. 2. Comparison of adjusted hazard ratios (HR) for major coronary events (lower table) and Kaplan–Meier curves (above) stratiﬁed by body mass index (BMI) and epicardial adipose
tissue (EAT) volume quartiles. BMI QI was ≤21.4 kg/m2 and QII–IV, ≥21.5 kg/m2. Low EAT volumewas b107mL (median) and high EAT volume, ≥107mL. *HRs were adjusted for age, sex
and log-transformed CAC score.
11H. Yamamoto et al. / IJC Metabolic & Endocrine 8 (2015) 7–12cardiovascular disease, obesity parameters such as EAT volume may
offer an additional means of identifying individuals at high risk of coro-
nary morbidity.
4.2. EAT volume, mortality and morbidity
Our ﬁndings suggest that the measurement of EAT volume could be
a clinically useful means of identifying high-risk patients among those
with low BMI and suspected CAD. Several studies have reported that in-
creased EAT volume is associatedwith adverse cardiovascular outcomes
in the general population independent of traditional cardiovascular risk
factors [6,23]. Our ﬁndings provide further evidence of this phenome-
non, but in a subgroup of patients with likely more advanced coronary
disease despite their low BMI.
We have previously demonstrated that low BMI with high EAT vol-
ume was associated with higher CAC score, suggesting that these char-
acteristicswere associatedwithmore severe coronary atherosclerosis. It
has been separately reported that EAT volume is associated with the
progression of CAC, especially in young subjects and those with an ini-
tially low CAC score, suggesting that EATmay promote early atheroscle-
rosis [24]. In our cohort, theHRadjusted for risk factorswas signiﬁcantly
higher than that in the low BMI, high EAT volume group.
4.3. Mechanisms that could explain the relationship between EAT volume
and coronary mortality
We found that high EAT volume increased the risk of major- and all
coronary morbidities in non-obese patients with suspected CAD, but
there was no association with all-cause mortality. Harada and col-
leagues reported that EAT volume was signiﬁcantly correlated with
BMI, serum triglyceride concentration and the triglyceride/HDL-
cholesterol ratio, but not with the plasma concentrations of
adipocytokines [8]. Furthermore, they showed that plasma adiponectin
and interleukin-6 concentrationswere signiﬁcantly correlatedwithVAT
area in patients with coronary plaque [8]. Adipocytokines or inﬂamma-
tory cytokines produced by EAT may promote coronary atherosclerosis
from outside the coronary vessel walls. Our ﬁndings resonate with a re-
cent report that EAT adiponectin concentration is a strong predictor of
cardiovascular prognosis in patients with cardiovascular disease [25].4.4. Study limitations
Ours was a retrospective study with a relatively small number of
participants to be generalized. Consequently, event rates were low:
all-cause deaths occurred in 31 patients (ﬁve cardiac deaths) and
major coronary events occurred in 18 patients. Such small numbers
may be misleading at all. A prospective multicenter trial is required to
conﬁrm our ﬁndings. Also, our study included only patients with
suspected CAD who underwent coronary CT, so our ﬁndings cannot be
generalized to individualswith a lower probability of CAD. Furthermore,
we were unable to illuminate whether excess BMI increased all-cause
mortality or all coronary morbidity. This could be explained by the rel-
atively low BMI of the cohort. Finally, we could not clarify the mecha-
nism by which the EAT accumulation contributed the occurrence of
coronary plaque rupture or erosion, and then enhanced the coronary
event rates. There were several histopathological studies in EAT [8,13,
26]. Our ongoing study (UMIN000010654) will support to clarify this
mechanism and to ﬁnd a new therapeutic target to prevent the onset
of acute coronary syndrome.5. Conclusions
The incidence of major coronary events (cardiac death and acute
coronary syndrome) was increased in patients with suspected CAD,
low BMI and high EAT volume. In contrast, high EAT volumewas not as-
sociated with all-cause mortality.Conﬂict of interest
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